NICE’s Off-Label Drug Guide Doesn’t Imply Support – Even For Pfizer
Executive Summary
With safety in mind, NICE is to publish product summaries on the off-label use of specific medicines, but stresses that this is not meant to encourage the practice.
You may also be interested in...
Avastin-Related Eye Infections Could Bring FDA Pressure On Compounding Pharmacies
An FDA alert about a cluster of Streptococcus endophthalmitis infections in Florida suggests concerns about aseptic conditions in pharmacies that repackage Avastin for off-label intravitreal use.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.